HanoiAs of 3 p.m. on March 5, 400 people registered to test Covivac, Vietnam’s second Covid-19 vaccine, mostly online.
A clinical trial officer said the volunteer recruitment process started at 8:00 this morning. There are two forms of registration, including online by phone, website, email and in person at 5th floor, building A1, Hanoi Medical University (HMU). The direct registration desks are open until 5pm daily, while the online registration hotline is available 24/24.
The direct registration point at HMU welcomes about 5 people on the afternoon of March 5, including two young men, a middle-aged person and a woman. Health staff explained about the recruitment process, screening and volunteer benefits. They kept the information if the subscriber had an underlying medical condition, the conditions for recruiting volunteers were not pregnant, and had another vaccination during the course of the female trial.
Due to the influence of Covid-19, the number of direct subscribers was small. From the morning of March 5, only about 10 people have registered directly at HMU. Nearly 400 others registered online via phone, website, email.
The male student of HMU, a 28-year-old from Ho Chi Minh City, one of those who signed up for the vaccine trial, said he understood and did not worry about vaccine side effects and possible abnormalities due to will be supported as much as possible by a specialist doctor. Before registering, he also learned all necessary information through teachers in the school.
The 53-year-old man, from Dong Da district, Hanoi, said: “Participated in the trial to check the health and wants to contribute to the early completion of the Covid-19 vaccine in Vietnam, completed, approved and injected. for the citizen”.
With the current progress, the research team expects the volunteer recruitment time to end soon. Thereafter, enrollees can be scheduled for a screening appointment in March 10-14, with the first injection on March 15-20.
Covivac is a Covid-19 vaccine researched and developed by the Institute of Vaccines and Medical Biologicals (IVAC). Phase one clinical trial requires 120 healthy people, aged 18-59, to test the safety and partial immunogenicity of the vaccine. This is the second vaccine from Vietnam to put into clinical trials. It is expected that phase one of the Covivac clinical trial will end in May 2021.
The first vaccine tested, Nanocovax, studied by Nanogen, has now entered the phase 2 clinical trial. By March 4, the phase 2 study had gone 65%. And Vabiotech is the third research unit for the Covid-19 vaccine, which has not submitted a clinical trial application.
Chile – Giang Huy